Technology | Patient Positioning Radiation Therapy | September 04, 2019

Apollo MR3T Laser Receives FDA 510(k) Clearance

High-precision room laser used for patient positioning in radiation therapy in an electromagnetic environment

Apollo MR3T Laser Receives FDA 510(k) Clearance

September 4, 2019 — LAP LLC announced its Apollo MR3T positioning laser for radiation therapy has received U.S. Food and Drug Administration (FDA) 510(k) approval. The magnetic resonance (MR)-compatible room laser is currently the only product of its class approved the FDA, according to the company.

Apollo MR3T are high-precision room lasers for patient positioning in an electromagnetic environment. They are used in classical radiation therapy for patient positioning during imaging with a magnetic resonance tomograph (MRT) and in MR-guided radiation therapy with MR-LINAC (linear accelerators). During regular quality assurance (QA), test phantoms such as the newly developed Thales 3-D MR scanner, are placed quickly and easily with the help of certified lasers.

The components of the Apollo MR3T have minimal ferromagnetic properties and have no influence on the imaging. They are magnetically safe and optimally adapted to magnetic field strengths up to 3 Tesla. 

The device is available as a single laser or as a customized laser bridge to meet the requirements of any room situation. 

A high-quality aluminum housing protects the fine mechanics and optical components inside the Apollo MR3T. Break-resistant glass withstands all the stresses and strains of everyday clinical life. Even at a distance of 4 meters, the maximum width of the laser line is 1 mm. The line straightness within the line shows only submillimeter deviations even at a distance of 3 meters. The adjustment of the lasers is conveniently controlled via remote control. The fast and stepless adjustment of laser position and focus saves time for QA tasks and irradiation.

For more information: www.lap-laser.com

Related Content

Members of Congress from both sides of the aisle issued a series of oversight letters to the Centers for Medicare and Medicaid Services (CMS) in recent months to urge the Agency to adjust its proposed radiation oncology advanced alternative payment model (RO Model)

Image by whitfieldink from Pixabay

News | Radiation Oncology | November 13, 2019
November 13, 2019 — Members of Congress from both sides of the aisle issued a series of oversight letters to the...
Bladder Abdomen Pelvis image with DLCExpert
News | Artificial Intelligence | November 07, 2019
November 7, 2019 — Mirada Medical, a global leader in...
Liver cancer tumor scanning using an MRI
News | Proton Therapy | November 04, 2019
November 4, 2019 – Two new studies support and inform the use of proton radiation therapy to treat patients with hepa
Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Feature | ASTRO | October 30, 2019 | By Greg Freiherr
At the American Society for Radiation Oncology’s (ASTRO) 2019 a
Advanced Radiation Therapy Upgrades AccuBoost Digital Brachytherapy Platform
News | Brachytherapy Systems, Women's Healthcare | October 23, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago, Advanced Radiation...
MD Anderson and Varian Partner to Optimize Radiation Oncology Treatment
News | Treatment Planning | October 18, 2019
The University of Texas MD Anderson Cancer Center and Varian announced a new strategic collaboration to develop an...
Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Feature | Prostate Cancer | October 16, 2019 | By Jeff Zagoudis
Radiation therapy is an important tool in the clinician’s armamentarium for treatment of localized, early-stage prost